Savings Distributors LLC - rezultati iskanja

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

donepezil sandoz distab 10mg tableta dispergovatelná v ústech

sandoz s.r.o., praha array - 14838 donepezil-hydrochlorid - tableta dispergovatelná v ústech - 10mg - donepezil

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

kognezil 10mg potahovaná tableta

zentiva, k.s., praha array - 14838 donepezil-hydrochlorid - potahovaná tableta - 10mg - donepezil

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

kognezil 5mg potahovaná tableta

zentiva, k.s., praha array - 14838 donepezil-hydrochlorid - potahovaná tableta - 5mg - donepezil

Evropska unija - češčina - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinurie, paroxysmální - selektivní imunosupresiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Evropska unija - češčina - EMA (European Medicines Agency)

ontilyv

bial portela & companhia s.a. - opicapone - parkinsonova choroba - antiparkinsonické léky - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

fresubin original s broskvovou pŘíchutí por sol 1x200ml